A person suspected of having Alzheimer's disease (AD) is clinically diagnosed for the
presence of principal biomarkers, especially misfolded amyloid-beta (Aβ) and tau proteins in …

The accumulation of amyloid fibrils is characteristic of neurodegenerative diseases such as
Alzheimer's disease (AD) and Parkinson's disease. Detecting these fibrils with fluorescent or …

Fibrillar protein aggregates are characteristic of neurodegenerative diseases but represent
difficult targets for ligand design, because limited structural information about the binding …

Abstract β‐amyloid (Aβ) is one of the important biomarkers for diagnosing Alzheimer's
disease (AD). Many near‐infrared probes based on the donor‐π‐acceptor structure have …

With accumulating evidence suggesting that amyloid-β (Aβ) deposition is a good diagnostic
biomarker for Alzheimer's disease (AD), the discovery of active Aβ probes has become an …

Alzheimer's disease (AD) is characterized by progressive decrease in cognitive abilities,
language impairment and irreversible memory loss. Amyloid-β (Aβ) and tau deposits are …

The advancements in the field of imaging and diagnostics have been benefitted by the
concurrent expansion of molecular probes space to monitor the diverse biological targets …

Three fluorescent organic compounds—furocoumarin (FC), dansyl aniline (DA), and 7-
hydroxycoumarin-3-carboxylic acid (CC)—are mixed to produce almost pure white light …

Fluorescent imaging of β-amyloid (Aβ) is one of the most promising methods for Alzheimer's
disease diagnosis. Several fluorescent probes have been reported to detect Aβ both in vitro …

BODIPY (4, 4-difluoro-4-bora-3a, 4a-diaza-s-indacene) derivatives have attracted attention
as probes in applications like imaging and sensing due to their unique properties like (1) …